A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 393-403

  Rainov, N G ^a,b   Sena Esteves, M ^a   Fraefel, C ^a   Dobberstein, K U ^b   Chiocca, E A ^a   Breakefield, X O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 IPOMEANOL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOSINE DEAMINASE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PLASMID DNA; PRODRUG; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENE TARGETING; GENE THERAPY; GLIOMA; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; TUMOR CELL;

EID: 0031784978     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_61     Document Type: Article

References (21)

1. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan P A, Paulus W, Chiocca EA, Breakefield XO,1995: Gene therapy for brain tumors. Brain Pathol 5, 345-381
2. Tamiya T, Ono Y, Wei MX, Mroz PJ, Moolten FL, Chiocca EA, 1996: Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther 3,155-162
3. Huber BE, Austin EA, Richards CA, Davis ST, Good SS, 1994: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant anti-tumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91, 8302-8306
4. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA, 1994; Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5, 969-978
5. Moolten FL, 1986: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46, 5276-5281
6. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE, 1995: Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55, 4808-4812
7. Boyd MR, Wilson BJ, Harris TM, 1972: Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nature New Biol 236,158-159
8. Boyd MR,1976: Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol. Environ. Health Perspect. 16, 127-138
9. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC, 1994: Green fluorescent protein as a marker for gene expression. Science 263, 802-805
10. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller Al, 1996: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70, 7190-7197
11. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Chiocca EA, Philpot RM, Breakefield XO, 1997: Prodrug activation therapy of malignant glioma with cytochrome P450 4B1. Human Gene Ther - in press
12. Dutcher JS, Boyd MR, 1979: Species and strain differences in target organ alkylation and toxicities by 4-Ipomeanol: predictive value of covalent binding in studies of target organ toxicities by reactive metabolites. Biochem Pharmacol 28, 3367-3372
13. Statham CN, Boyd MR, 1982: Distribution and metabolism of the pulmonary alkylating agent and cytotoxin, 4-ipomeanol, in control and diethylmaleate-treated rats. Biochem Pharmacol 31, 1585-1589
14. Verschoyle RD, Philpot RM, Wolf CR, Dinsdale D, 1993: CYP4B1 activates 4-Ipomeanol in rat lung. Toxicol Appl Pharmacol 123, 193-198
15. Czerwinski M, McLemore TL, Philpot RM, Nhamburo PT, Korzekwa K, Gelboin HV, Gonzalez FJ, 1991: Metabolic activation of 4-Ipomeanol by complementary DNA-expressed human cytochromes p-450: evidence for species-specific metabolism. Cancer Res 51, 4636-4638
16. Boyd MR, Burka LT, 1978: In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J Pharmacol Exp Ther 207, 687-697
17. Smith PB, Tiano HF, Nesnow S, Boyd MR, Philpot RM, Langenbach R, 1995: 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4BI. Biochem Pharmacol 50, 1567-1575
18. Vanderslice RR, Domin BA, Carver GT, Philpot RM, 1987: Species-dependent expression and induction of homologues of rabbit cytochrome p-450 isozyme 5 in liver and lung. Mol Pharmacol 31, 320-325
19. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN, 1993: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53, 5274-5283
20. Manome Y, Wen PY, Chen L, Tanaka T, Dong Y, Yamazoe M, Hirshowitz A, Kufe DW, Fine HA, 1996: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2BI gene together with cyclophosphamide. Gene Ther 3, 513-520
21. Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW, 1995: A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery 36, 976-984